Cargando…
Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?
INTRODUCTION: To evaluate the actual perceptions of hormonal contraceptives (HC) in women of reproductive age in comparison with similar concerns of postmenopausal women in relation to hormone therapy (HT). MATERIALS AND METHODS: A questionnaire-based study was conducted in a population of 370 women...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205098/ https://www.ncbi.nlm.nih.gov/pubmed/34124968 http://dx.doi.org/10.1080/07853890.2021.1938662 |
_version_ | 1783708441261375488 |
---|---|
author | Grandi, Giovanni Del Savio, Maria Chiara Boggio Sola, Valentina Monari, Francesca Melotti, Chiara Facchinetti, Fabio |
author_facet | Grandi, Giovanni Del Savio, Maria Chiara Boggio Sola, Valentina Monari, Francesca Melotti, Chiara Facchinetti, Fabio |
author_sort | Grandi, Giovanni |
collection | PubMed |
description | INTRODUCTION: To evaluate the actual perceptions of hormonal contraceptives (HC) in women of reproductive age in comparison with similar concerns of postmenopausal women in relation to hormone therapy (HT). MATERIALS AND METHODS: A questionnaire-based study was conducted in a population of 370 women, 198 (53.5%) premenopausal and 172 (46.5%) postmenopausal. Perceptions were evaluated using specific questions and Likert scales (-5 to +5).Multivariate regression analyses were adjusted for categories of HC/HT use (never, past and current). RESULTS: The most reported adverse effect associated with hormonal treatments was venous thrombosis (1.4 ± 0.1), especially for HC use in premenopausal women (p < .0001). According to responses, hormonal treatments can increase the risk of developing venous thrombosis (OR 0.79; 95% CI 0.67–0.96, p = .004) and depression (OR 0.80; 95% CI 0.69–0.92, p = .002) more in pre-menopause, while they can increase the risk of weight gain more in post-menopause (OR 1.24: 95% CI 1.07–1.42, p = .003).The greatest oncological concern throughout life was about breast cancer (0.9 ± 0.1). There was the perception that hormonal treatments can increase the risk of developing ovarian cancer more in post-menopause (OR 1.44; 95% CI 1.19–1.75, p = .0002), while they can increase the risk of uterine cervix cancer more in pre-menopause (OR 0.74; 95% CI 0.52–0.97, p = .03). CONCLUSIONS: Our data suggest that our patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk, and, later in life, about their impact on weight gain, breast and ovarian cancer risk. KEY MESSAGES: 1. Young patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk. 2. Older patients are primarily concerned about the effects of hormonal treatments on weight gain, breast and ovarian cancer risk. 3. The greatest oncological concern throughout life was about breast cancer. |
format | Online Article Text |
id | pubmed-8205098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-82050982021-06-24 Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause? Grandi, Giovanni Del Savio, Maria Chiara Boggio Sola, Valentina Monari, Francesca Melotti, Chiara Facchinetti, Fabio Ann Med Pregnancy, Childbirth & Women’s Health INTRODUCTION: To evaluate the actual perceptions of hormonal contraceptives (HC) in women of reproductive age in comparison with similar concerns of postmenopausal women in relation to hormone therapy (HT). MATERIALS AND METHODS: A questionnaire-based study was conducted in a population of 370 women, 198 (53.5%) premenopausal and 172 (46.5%) postmenopausal. Perceptions were evaluated using specific questions and Likert scales (-5 to +5).Multivariate regression analyses were adjusted for categories of HC/HT use (never, past and current). RESULTS: The most reported adverse effect associated with hormonal treatments was venous thrombosis (1.4 ± 0.1), especially for HC use in premenopausal women (p < .0001). According to responses, hormonal treatments can increase the risk of developing venous thrombosis (OR 0.79; 95% CI 0.67–0.96, p = .004) and depression (OR 0.80; 95% CI 0.69–0.92, p = .002) more in pre-menopause, while they can increase the risk of weight gain more in post-menopause (OR 1.24: 95% CI 1.07–1.42, p = .003).The greatest oncological concern throughout life was about breast cancer (0.9 ± 0.1). There was the perception that hormonal treatments can increase the risk of developing ovarian cancer more in post-menopause (OR 1.44; 95% CI 1.19–1.75, p = .0002), while they can increase the risk of uterine cervix cancer more in pre-menopause (OR 0.74; 95% CI 0.52–0.97, p = .03). CONCLUSIONS: Our data suggest that our patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk, and, later in life, about their impact on weight gain, breast and ovarian cancer risk. KEY MESSAGES: 1. Young patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk. 2. Older patients are primarily concerned about the effects of hormonal treatments on weight gain, breast and ovarian cancer risk. 3. The greatest oncological concern throughout life was about breast cancer. Taylor & Francis 2021-06-14 /pmc/articles/PMC8205098/ /pubmed/34124968 http://dx.doi.org/10.1080/07853890.2021.1938662 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pregnancy, Childbirth & Women’s Health Grandi, Giovanni Del Savio, Maria Chiara Boggio Sola, Valentina Monari, Francesca Melotti, Chiara Facchinetti, Fabio Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause? |
title | Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause? |
title_full | Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause? |
title_fullStr | Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause? |
title_full_unstemmed | Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause? |
title_short | Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause? |
title_sort | attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause? |
topic | Pregnancy, Childbirth & Women’s Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205098/ https://www.ncbi.nlm.nih.gov/pubmed/34124968 http://dx.doi.org/10.1080/07853890.2021.1938662 |
work_keys_str_mv | AT grandigiovanni attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause AT delsaviomariachiara attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause AT boggiosolavalentina attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause AT monarifrancesca attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause AT melottichiara attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause AT facchinettifabio attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause |